Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05954871
Title Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Genentech, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | CAN | AUS

Facility Status City State Zip Country Details
Stanford Advanced Medical Center Stanford California 94305 United States Details
Yale Cancer Center New Haven Connecticut 06510 United States Details
Christiana Care Health System Newark Delaware 19713 United States Details
SCRI Oncology Partners Nashville Tennessee 37203 United States Details
MD Anderson Cancer Center Houston Texas 77030 United States Details
START South Texas Accelerated Research Therapeutics-San Antonio San Antonio Texas 78229 United States Details
Border Medical Oncology Wodonga New South Wales 3690 Australia Details
The Queen Elizabeth Hospital Woodville South Australia 5011 Australia Details
St Vincent's Hospital Melbourne Fitzroy Victoria 3065 Australia Details
Peter Maccallum Cancer Centre Melbourne Victoria 3000 Australia Details
British Columbia Cancer Agency Vancouver British Columbia V5Z 4E6 Canada Details
Ottawa Hospital Ottawa Ontario K1H 8L6 Canada Details
Princess Margaret Cancer Centre Toronto Ontario M5G 1Z5 Canada Details
Seoul National University Hospital Seoul 03080 Korea, Republic of Details
Asan Medical Center Seoul 05505 Korea, Republic of Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field